Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Glucose Monitoring Oct 10 | 2022Indigo Expands Multi-Metabolite Sensor Development; GlucoTrack to Develop CGM for T1DM; AZ Initiates New Dapa + Zibotentan Ph2 Trial; Sciwind Initiates Patient Dosing in Ph1 Oral GLP-1RA Trial; Ascensia Completes Initial European E3 CGM Launch; October CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA + Basal, Glucose Monitoring, Other Oct 07 | 2022Abbott Expands Libre 3 Distribution to Pharmacy; Second Ph3 Cagrisema Trial Posted on CT.gov; Galectin NASH Trial to Continue After Second DSMB MeetingPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 06 | 2022Tirzepatide Receives Fast Track Designation in Obesity; Provention Bio and Sanofi Join Forces for Potential Teplizumab US LaunchPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 04 | 2022Dexcom Expands ex-US G7 Launch; Novo to Initiate OASIS 4 Ph3 Oral Sema Obesity Trial; Lilly to Initiate two Lp(a) Ph2 Trials; Better Therapeutic Publishes BT-001 Pivotal Trial Results in Diabetes CarePurchase Blast
$599
Posted in: Basal Insulin Oct 03 | 2022Novo’s QW Insulin Icodec Meets Primary Endpoint in ONWARDS 5Purchase Blast
$599
Posted in: Other Sep 30 | 2022Novo Nordisk and Ventus Therapeutics Partner for NASH; Intercept’s OCA Misses Primary Endpoint in Ph3 REVERSE Trial; Beta Bionics Publishes Pivotal Trial Results in NEJM; Diamyd Completes Dosing Patients in DIAGNODE-B Booster TrialPurchase Blast
$599
Posted in: Other Sep 28 | 2022Dexcom Invests in Nutromics $14M Series B; Vertex and MaxCyte Partnership for CRISPR/Cas9-based Gene-editing ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Sep 27 | 2022Tirzepatide Approved in Japan; Nemaura and EVERSANA Partner for BEATdiabetes; SURMOUNT-MMO Trial Record PostedPurchase Blast
$599
Posted in: Other Sep 23 | 2022New ADA/EASD 2022 T2DM Guidelines; EASD 2022 Key Press Releases (Sept 23)Purchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, GLP-1RA + Basal, Other Sep 23 | 2022EASD 2022 Key Press Releases (Sept 22)Purchase Blast
$599
Posted in: GLP-1RA Sep 22 | 2022Pfizer to Advance Oral GLP-1RA Development; Pfizer EASD 2022 Investor CallPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery Sep 21 | 2022Lilly’s Tempo Smart Button Receives 510(k) Clearance; EASD 2022 Key Press Releases (Sept 21)Purchase Blast$599
Posted in: Dual/triple agonist Sep 21 | 2022SURMOUNT-MMO Trial Design Presented at EASD 2022Purchase Blast$599
Posted in: Insulin Delivery, Other Sep 20 | 2022Insulet Omnipod 5 Receives CE Mark; Novo Nordisk and Octagon Therapeutics Collaboration for Inflammatory Disease Targets; Diamyd Presents Updated 12-month Results from Ph2 GADinLADA Trial; EASD 2022 Key Press Releases (Sept 20)Purchase Blast$599
Posted in: Insulin Delivery, Other Sep 19 | 2022Biocorp’s SoloSmart receives CE Mark; EASD 2022 Key Press Releases (Sept 19)Purchase Blast
$599
Posted in: Basal Insulin Sep 19 | 2022Tresiba AG vs. Basal Insulin Pricing AnalysisPurchase Blast
$599
Posted in: Other Sep 15 | 2022Alnylam and Regeneron to Advance NASH ALN-HSD AssetPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Sep 13 | 2022Akero Becomes a Frontrunner in NASH; Lilly Initiates Tirzepatide Ph2 TREASURE-CKD Trial; Oramed’s Oral Insulin Ph2 NASH Topline ResultsPurchase Blast